Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The combination melphalan-prednisone-thalidomide (MPT) is considered a standard therapy for patients with myeloma who are ineligible for stem-cell transplantation. However, emerging data on the use of lenalidomide and low-dose dexamethasone warrant a prospective comparison of the two approaches. METHODS: We randomly assigned 1623 patients to lenalidomide and dexamethasone in 28-day cycles until disease progression (535 patients), to the same combination for 72 weeks (18 cycles; 541 patients), or to MPT for 72 weeks (547 patients). The primary end point was progression-free survival with continuous lenalidomide-dexamethasone versus MPT. RESULTS: The median progression-free survival was 25.5 months with continuous lenalidomide-dexamethasone, 20.7 months with 18 cycles of lenalidomide-dexamethasone, and 21.2 months with MPT (hazard ratio for the risk of progression or death, 0.72 for continuous lenalidomide-dexamethasone vs. MPT and 0.70 for continuous lenalidomide-dexamethasone vs. 18 cycles of lenalidomide-dexamethasone; P<0.001 for both comparisons). Continuous lenalidomide-dexamethasone was superior to MPT for all secondary efficacy end points, including overall survival (at the interim analysis). Overall survival at 4 years was 59% with continuous lenalidomide-dexamethasone, 56% with 18 cycles of lenalidomide-dexamethasone, and 51% with MPT. Grade 3 or 4 adverse events were somewhat less frequent with continuous lenalidomide-dexamethasone than with MPT (70% vs. 78%). As compared with MPT, continuous lenalidomide-dexamethasone was associated with fewer hematologic and neurologic toxic events, a moderate increase in infections, and fewer second primary hematologic cancers. CONCLUSIONS: As compared with MPT, continuous lenalidomide-dexamethasone given until disease progression was associated with a significant improvement in progression-free survival, with an overall survival benefit at the interim analysis, among patients with newly diagnosed multiple myeloma who were ineligible for stem-cell transplantation. (Funded by Intergroupe, Francophone du Myélome and Celgene; FIRST ClinicalTrials.gov number, NCT00689936; European Union Drug Regulating Authorities Clinical Trials number, 2007-004823-39.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Lenalidomide plus dexamethasone is a standard treatment for patients with newly diagnosed multiple myeloma who are ineligible for autologous stem-cell transplantation.”
From Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma (2019) · cites this paper as [5]
In the citing paper
“However, the incidence of grade 3 or 4 infections was 29% with lenalidomide and dexamethasone in the primary analysis of the FIRST trial,5 which was consistent with the incidence in our trial (32.1% in the daratumumab group and 23.3% in the control group).”
From Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma (2019) · cites this paper as [5]
In the citing paper
“In this subset of patients, maintenance therapy with proteasome inhibitors alone or in combination with lenalidomide seems to be more effective than single-agent lenalidomide34,35.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [34]
In the citing paper
“Patients with high-risk cytogenetic features might be the only exception, although they do derive a progression-free survival (PFS) benefit34,35.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [34]
In the citing paper
“The most worrisome adverse effect observed in studies of lenalidomide maintenance therapy is an up to six-fold increase in the risk of second primary malignancies, in particular, MDS and acute myeloid leukaemia (AML): 5.3% versus 0.8% with placebo or observation34.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [34]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982) · AMERICAN JOURNAL OF CLINICAL ONCOLOGY · doi:10.1097/00000421-198212000-00014 · Cited by 11,647
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
International uniform response criteria for multiple myeloma
Durie, B. G. M., Harousseau, J.-L., Miguel, J. S., Bladé, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404284 · Cited by 2,632
Self-citationPalumbo, A., & Anderson, K. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1011442 · Cited by 2,326
Self-citationRaje, N., & Anderson, K. C. (2000) · Current Treatment Options in Oncology · doi:10.1007/s11864-000-0017-x · Cited by 2,163
Self-citationBortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
San Miguel, J. F., Schlag, R., Khuageva, N. K., Dimopoulos, M. A., Shpilberg, O., Kropff, M., Spicka, I., Petrucci, M. T., Palumbo, A., Samoilova, O. S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801479 · Cited by 1,899
Self-citationGroup sequential methods in the design and analysis of clinical trials
POCOCK, S. J. (1977) · Biometrika · doi:10.1093/biomet/64.2.191 · Cited by 1,831
Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
Dimopoulos, M., Spencer, A., Attal, M., Prince, H. M., Harousseau, J.-L., Dmoszynska, A., Miguel, J. S., Hellmann, A., Facon, T., Foà, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070594 · Cited by 1,450
Self-citationLenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America
Weber, D. M., Chen, C., Niesvizky, R., Wang, M., Belch, A., Stadtmauer, E. A., Siegel, D., Borrello, I., Rajkumar, S. V., Chanan-Khan, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070596 · Cited by 1,233
Self-citation
Cited by
Items 301–400 of 793
Efficace, F., Cottone, F., Sparano, F., Caocci, G., Vignetti, M., & Chakraborty, R. (2022) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2022.01.009 · Cited by 19
Costa, B. A., Mouhieddine, T. H., Ortiz, R. J., & Richter, J. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104040 · Cited by 18
Cella, D. F., McKendrick, J., Kudlac, A., Palumbo, A. P., Oukessou, A., Vij, R., Zyczynski, T. M., & Davis, C. (2018) · Annals of Hematology · doi:10.1007/s00277-018-3469-4 · Cited by 19
Larocca, A., Mina, R., Offidani, M., Liberati, A. M., Ledda, A., Patriarca, F. F., Evangelista, A., Spada, S., Benevolo, G., Oddolo, D., et al. (2019) · Haematologica · doi:10.3324/haematol.2019.220657 · Cited by 18
Terebelo, H. R., Abonour, R., Gasparetto, C., TOOMEY, K. E., Durie, B. G. M., Hardin, J. W., Jagannath, S., Wagner, L. I., Narang, M., Flick, E. D., et al. (2019) · British Journal of Haematology · doi:10.1111/bjh.16139 · Cited by 21
Uno, S., Goto, R., Suzuki, K., Iwasaki, K., Takeshima, T., & Ohtsu, T. (2019) · Journal of Medical Economics · doi:10.1080/13696998.2019.1686870 · Cited by 18
Updated Perspectives on the Management of Multiple Myeloma in Older Patients: Focus on Lenalidomide
Schoenbeck, K. L., & Wildes, T. M. (2020) · Clinical Interventions in Aging · doi:10.2147/cia.s196087 · Cited by 18
“Second Primary Malignancies Several studies reported an increased risk of developing a second primary malignancy after treatment with lenalidomide in a melphalan-containing regimen or as maintenance post-ASCT.(20,25,33,46) A pooled analysis of 11 clinical trials of relapsed multiple myeloma treated with lenalidomide r…”
BackgroundInfluentialLemieux, C., Muffly, L. S., Rezvani, A. R., Lowsky, R., Iberri, D. J., Craig, J. K., Frank, M. J., Johnston, L., Liedtke, M., Negrin, R. S., et al. (2020) · Bone Marrow Transplantation · doi:10.1038/s41409-020-01026-7 · Cited by 19
Murthy, H. S., & Wood, W. A. (2015) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-015-0261-6 · Cited by 19
A Benefit–Risk Analysis Approach to Capture Regulatory Decision‐Making: Multiple Myeloma
Raju, G. K. P., Gurumurthi, K., Domike, R., Kazandjian, D. G., Landgren, O., Blumenthal, G. M., Farrell, A. T., Pazdur, R., & Woodcock, J. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.871 · Cited by 19
“The experimental drug arm demonstrated a 10-month OS advantage over the control.(31) This advantage in OS may have been taken into account in the regulatory decision to approve lenalidomide in combination with dexamethasone as a first-line treatment for MM.”
BackgroundGlobal Myeloma Trial Participation and Drug Access in the Era of Novel Therapies
Fatoki, R. A., Koehn, K., Kelkar, A. H., Hadidi, S. A., Mehra, N., Mian, H. S., Landgren, O., Kazandjian, D. G., Hoffman, J. E., Sborov, D. W., et al. (2022) · JCO Global Oncology · doi:10.1200/go.22.00119 · Cited by 20
Lu, J., Lee, J. H., Huang, S., Qiu, L., Lee, J., Liu, T., Yoon, S., Kım, K., Shen, Z. X., Eom, H., et al. (2017) · British Journal of Haematology · doi:10.1111/bjh.14465 · Cited by 18
Self-citationGrant, S. J., Mian, H. S., Giri, S., Boutin, M., Dottorini, L., Neuendorff, N. R., Krok‐Schoen, J. L., Nikita, N., Rosko, A. E., Wildes, T. M., et al. (2020) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2020.12.001 · Cited by 19
Evolution of Treatment Paradigms in Newly Diagnosed Multiple Myeloma
Elnair, R. A., & Holstein, S. A. (2021) · Drugs · doi:10.1007/s40265-021-01514-0 · Cited by 18
“Lenalidomide and dexamethasone (Rd) continued until progression was established as a new standard of care based on results from the FIRST trial [29].”
MethodCurrent Treatment Approaches to Newly Diagnosed Multiple Myeloma
Ghandili, S., Weisel, K. C., Bokemeyer, C., & Leypoldt, L. B. (2021) · Oncology Research and Treatment · doi:10.1159/000520504 · Cited by 18
Self-citationArnall, J. R., Maples, K. T., Harvey, R. D., & Moore, D. C. (2021) · Annals of Pharmacotherapy · doi:10.1177/10600280211058754 · Cited by 20
Cohen, Y. C., Joffe, E., Benyamini, N., Dimopoulos, M. A., Terpos, E., Trestman, S., Held, V., Avivi, I. M., & Kastritis, E. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2015.1121258 · Cited by 17
“[15–18] However, some recent reports suggest that among elderly or frail patients, addition of alkylators may not necessarily be beneficial.[5,19,20] While in vitro studies [21,22] suggest that bortezomib may sensitize myeloma cells toward chemotherapy, it is unclear whether the addition of an alkylator overcomes bort…”
BackgroundSelf-citationD’Agostino, M., Paoli, L. D., Conticello, C., Offidani, M., Ria, R., Petrucci, M. T., Spada, S., Marcatti, M., Catalano, L., Gilestro, M., et al. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.09.008 · Cited by 17
Multiple Myeloma: Clinical Updates From the American Society of Hematology Annual Meeting 2016
Terpos, E. (2017) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2017.02.010 · Cited by 16
“Updated Survival Data from the First Trial *HR for the comparison between Rd continuous and MPT”
InfluentialKunacheewa, C., Lee, H. C., Patel, K. K., Thomas, S. K., Amini, B., Srour, S. A., Bashir, Q., Nieto, Y. L., Qazilbash, M. H., Weber, D. M., et al. (2020) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2020.01.001 · Cited by 17
Treatment of older adult or frail patients with multiple myeloma
Grant, S. J., Freeman, C. L. L., & Rosko, A. E. (2021) · Hematology · doi:10.1182/hematology.2021000231 · Cited by 18
Giles, H. V., & Karunanithi, K. (2024) · Antibodies · doi:10.3390/antib13010019 · Cited by 23
Nielsen, L. K., Abildgaard, N., Jarden, M., & Klausen, T. (2019) · British Journal of Haematology · doi:10.1111/bjh.15759 · Cited by 20
“Elderly and HDT-ineligible patients are treated with longer induction treatment for 8–12 months and in some patients, treatment is continued until relapse (Benboubker et al, 2014; Stewart et al, 2015a).”
BackgroundKubo, K., Hori, M., Ohta, K., Handa, H., Hatake, K., Matsumoto, M., Hagiwara, S., Ohashi, K., Nakaseko, C., Suzuki, K., et al. (2019) · International Journal of Hematology · doi:10.1007/s12185-019-02757-0 · Cited by 16
Bonello, F., Boccadoro, M., & Larocca, A. (2020) · Cancers · doi:10.3390/cancers12113106 · Cited by 18
Cejalvo, M. J., Bustamante, G., González, E., Vázquea-Álvarez, J., García, R., Ramírez-Payer, Á., Persona, E. P., Abella, E., Garzón, S., García, A., et al. (2021) · Annals of Hematology · doi:10.1007/s00277-021-04529-5 · Cited by 17
“Remarkably, the frequency of the VISTA VMP regimen also dropped with age (from 31% for patients aged ≤ 75 years to 11% for those aged > 80 years); however, the regimens more frequently administered in these patients, such MP, have lower anti-myeloma efficacy [21].”
BackgroundNonproportional Hazards—An Evaluation of the MaxCombo Test in Cancer Clinical Trials
Shen, Y.-L., Wang, X., Sirisha, M., Mulkey, F. A., Zhou, J., Gao, X., Zhang, L., Gwise, T. E., Tang, S. W., Theoret, M. R., et al. (2021) · Statistics in Biopharmaceutical Research · doi:10.1080/19466315.2021.2008485 · Cited by 16
Ludwig, H., Delforge, M., Facon, T. T. F., Einsele, H., Gay, F., Moreau, P., Avet‐Loiseau, H., Boccadoro, M., Hájek, R., Mohty, M., et al. (2017) · Leukemia · doi:10.1038/leu.2017.353 · Cited by 19
Self-citationNew pharmacotherapy options for multiple myeloma
Mina, R., Cerrato, C., Bernardini, A., Aghemo, E., & Palumbo, A. P. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2016.1115016 · Cited by 18
“MPT Mel-P-Thal 815 59% Median PFS: 20,3 mo Hematologic AEs: 32% Fayers [5] Median OS: 39,3 mo Infection: 13% Peripheral neuropathy: 6% Deep-vein-thrombosis: 6% RD Len 25 mg on days 1–21 223 79% 1-year OS: 87% Fatigue: 15% Rajkumar [7] Dex 40 mg on days 1–4, 9–12, and 17–20 of a 28-day cycle Pneumonia: 16% Deep-vein-th…”
BackgroundResultHus, I., Walter‐Croneck, A., Masternak, A., Jurczyszyn, A. J., Usnarska‐Zubkiewicz, L., Bołkuń, Ł., Druzd‐Sitek, A., Rymko, M., Łętowska, J., Lech‐Marańda, E., et al. (2017) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.4099 · Cited by 18
Xu, J., Zou, J., Zhang, D., Zhang, K., Qi, Y., Yan, C., Lee, E., Jia, Q., Ma, C., & Jiang, H. B. (2025) · Progress in Materials Science · doi:10.1016/j.pmatsci.2025.101541 · Cited by 16
Dimopoulos, M. A., Laubach, J. P., Gutierrez, M. A. E., Grząśko, N., Hofmeister, C. C., Miguel, J. F. S., Kumar, S. K., Labotka, R., Lu, V., Berg, D. T., et al. (2019) · European Journal Of Haematology · doi:10.1111/ejh.13231 · Cited by 16
Self-citationChan, H. S. H., Chai, K., Shih, S., Lewsey, R., Chen, K. Y., McDiarmid, B., Jackson, S., & Simpson, D. (2019) · British Journal of Haematology · doi:10.1111/bjh.16095 · Cited by 16
“Indeed, the combination of bortezomib-thalidomide-dexamethasone (VTD) has been shown to be superior to bortezomibcyclophosphamide-dexamethasone (VCD) in transplant eligible patients (Cavo et al, 2015; Moreau et al, 2016).”
BackgroundMina, R., Bonello, F., Petrucci, M. T., Liberati, A. M., Conticello, C., Ballanti, S., Musto, P., Olivieri, A., Benevolo, G., Capra, A., et al. (2020) · Haematologica · doi:10.3324/haematol.2019.243428 · Cited by 15
“High risk was defined by the presence of at least one chromosomal abnormality, including t(4;14), del17p and t(14;16).”
BackgroundMethodResultInfluentialSelf-citationUsing Surrogate Endpoints in Adaptive Designs with Delayed Treatment Effect
Li, Q., Lin, J., Liu, M., Wu, L., & Liu, Y. (2021) · Statistics in Biopharmaceutical Research · doi:10.1080/19466315.2021.1938203 · Cited by 18
“The delayed treatment effect observed in many clinical trials (Benboubker et al. 2014; Borghaei et al. 2015; Reck et al. 2016) have presented the unique challenges in power calculation, treatment effect estimation, and interim decision making in adaptive designs.”
BackgroundCosta, B. A., Mouhieddine, T. H., & Richter, J. R. (2022) · Targeted Oncology · doi:10.1007/s11523-022-00897-8 · Cited by 21
Park, S., Lee, J. C., Byun, J. M., Choi, G., Kim, K., Lim, S., Dingli, D., Jeon, Y., Yahng, S., Shin, S., et al. (2023) · npj Precision Oncology · doi:10.1038/s41698-023-00385-w · Cited by 18
“Lenalidomide plus dexamethasone (RD) has also been used in frail and/or elderly ASCT-ineligible NDMM patients for better tolerability 18,19 .”
Self-citationEvolving Paradigms in the Management of Multiple Myeloma: Novel Agents and Targeted Therapies
Larsen, J. T., & Kumar, S. K. (2015) · Rare Cancers and Therapy · doi:10.1007/s40487-015-0009-4 · Cited by 14
“The FIRST trial randomized transplant-ineligible patients to either lenalidomide/dexamethasone for 18 cycles, until disease progression, or MPT for 18 cycles [37].”
MethodAre maintenance and continuous therapies indicated for every patient with multiple myeloma?
Musto, P., & Montefusco, V. (2016) · Expert Review of Hematology · doi:10.1080/17474086.2016.1196127 · Cited by 15
“(Rd-18), or 12 cycles of oral melphalan-prednisone-thalidomide (MPT) [31].”
BackgroundThe role of SLAMF7 in multiple myeloma: impact on therapy
Boudreault, J., Touzeau, C., & Moreau, P. (2016) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2016.1209112 · Cited by 16
“increases with age, the majority of patients are ineligible for autologous HSCT and studies have demonstrated that novel agents improve survival in this population [16].”
BackgroundSelf-citationSuzuki, K., Ri, M., Chou, T., Sugiura, I., Takezako, N., Sunami, K., Ishida, T., Izumi, T., Ozaki, S., Shumiya, Y., et al. (2017) · Cancer Science · doi:10.1111/cas.13166 · Cited by 15
Beijers, A. J. M., Oerlemans, S., Mols, F., Eurelings, M., Minnema, M. C., Vreugdenhil, A., & van de Poll-Franse, L. V. (2017) · Annals of Hematology · doi:10.1007/s00277-017-2927-8 · Cited by 16
Management of Multiple Myeloma
Kumar, S. K. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0040 · Cited by 15
Ntanasis‐Stathopoulos, I., Terpos, E., & Dimopoulos, M. A. (2019) · The Cancer Journal · doi:10.1097/ppo.0000000000000348 · Cited by 15
Self-citationTherapy-related myeloid neoplasms after treatment for plasma-cell disorders
Chung, A., & Liedtke, M. (2019) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2019.02.003 · Cited by 15
Stella, F., Pedrazzini, E., Agazzoni, M., Ballester, O., & Slavutsky, I. R. (2015) · Cancer Investigation · doi:10.3109/07357907.2015.1080833 · Cited by 21
Lee, Q., Mocarski, M., & Sun, S. X. (2016) · PubMed Central · Cited by 14
Connarn, J. N., Hwang, R., Gao, Y., Palmisano, M., & Chen, N. (2017) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.372 · Cited by 15
Monoclonal Antibody: A New Treatment Strategy against Multiple Myeloma
Cho, S., Lin, L., Xing, L., Yu, T., Wen, K., Anderson, K. C., & Tai, Y. (2017) · Antibodies · doi:10.3390/antib6040018 · Cited by 16
Self-citationSekine, L., Ziegelmann, P. K., Manica, D., Pithan, C. D. F., Sosnoski, M., Morais, V. D., Falcetta, F. S., Ribeiro, M. R., Salazar, A. P., & Ribeiro, R. A. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.07.001 · Cited by 15
Ikaros Proteins in Tumor: Current Perspectives and New Developments
Xia, R., Cheng, Y., Han, X., Wei, Y., & Wei, X. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.788440 · Cited by 19
“Patients with newly diagnosedMM (NDMM)whowere unsuitable for stem cell transplantation are associated with a considerable benefit in progression-free survival (PFS) [lenalidomide-dexamethasone vs. melphalan-prednisone-thalidomide (MPT); HR, 0.72; p < 0.001] and overall survival (OS) at the interim analysis and less fr…”
BackgroundInfluentialMaintenance therapy for multiple myeloma in the era of novel agents
Facon, T. T. F. (2015) · Hematology · doi:10.1182/asheducation-2015.1.279 · Cited by 16
Self-citationRichardson, P. G. G., Holstein, S. A., Schlossman, R. L., Anderson, K. C., Attal, M., & McCarthy, P. L. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1409207 · Cited by 14
Self-citationRifkin, R. M., Jagannath, S., Durie, B. G. M., Narang, M., Terebelo, H. R., Gasparetto, C., TOOMEY, K. E., Hardin, J. W., Wagner, L. I., Parikh, K., et al. (2018) · Clinical Therapeutics · doi:10.1016/j.clinthera.2018.05.017 · Cited by 14
“Age Median (range), y 60 (27 75) 60 (24 74) 60 (24 78) Group <65 y 113 (68) 127 (71) 171 (67) 65 <75 y 51 (31) 53 (29) 82 (32) Male 93 (56) 108 (60) 159 (62) Race White 139 (84) 152 (84) 221 (86) Black 18 (11) 22 (12) 27 (11) Asian 1 (1) 0 1 (<1) Other 1 (1) 2 (1) 2 (1) Not specified 6 (4) 4 (2) 5 (2) ECOG PS 0 or 1 1…”
Lin, H. M., Davis, K. L., Kaye, J. A., Luptakova, K., Nagar, S. P., & Mohty, M. (2019) · Advances in Hematology · doi:10.1155/2019/4625787 · Cited by 14
Suzuki, K., Shinagawa, A., Uchida, T., Taniwaki, M., Hirata, H., Ishizawa, K., Matsue, K., Ogawa, Y., Shimizu, T., Otsuka, M., et al. (2016) · Cancer Science · doi:10.1111/cas.12916 · Cited by 16
Self-citationTreatment of Multiple Myeloma in Elderly Patients: A Review of Literature and Practice Guidelines
Manapuram, S., & Hashmi, H. (2018) · Cureus · doi:10.7759/cureus.3669 · Cited by 18
Mohty, M., Knauf, W. U., Romanus, D., Corman, S. L., Verleger, K., Kwon, Y., Cherepanov, D., Cambron‐Mellott, M. J., Vikis, H. G., Gonzalez, F., et al. (2020) · European Journal Of Haematology · doi:10.1111/ejh.13439 · Cited by 16
“001 1 383 (46) 153 (57) 103 (48) 19 (14) 108 (50) 2 263 (31) 78 (29) 90 (42) 19 (14) 76 (35) 3 57 (7) 22 (8) 12 (6) 5 (4) 18 (8) 4 9 (1) 2 (1) 4 (2) 3 (2) 0 (0) Unknown 78 (9) 4 (1) 0 (0) 74 (54) 0 (0) Frailty status, n (%) Fit 130 (16) 93 (35) 10 (5) 7 (5) 20 (9) <.”
InfluentialCost-effectiveness of bortezomib for multiple myeloma: a systematic review
Chen, W., Yang, Y., Chen, Y., Du, F., & Zhan, H. (2016) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s104195 · Cited by 14
“Thus, the superior treatment efficacy associated with continuous RD relative to MPT in the FIRST trial 38 was applied to the comparisons for continuous RD versus VMP.”
Concise review ‐ Treatment of multiple myeloma in the very elderly: How do novel agents fit in?
Kint, N., & Delforge, M. (2016) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2016.08.001 · Cited by 15
Self-citationNuclear medicine imaging of multiple myeloma, particularly in the relapsed setting
Waal, E. G. M. D., Glaudemans, A. W. J. M., Schröder, C. P., Vellenga, E., & Slart, R. H. J. A. (2016) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-016-3576-1 · Cited by 16
New Strategies for the Treatment of Older Myeloma Patients
Larocca, A., Cani, L., Bertuglia, G., Bruno, B., & Bringhen, S. (2023) · Cancers · doi:10.3390/cancers15102693 · Cited by 18
Spotlight on elotuzumab in the treatment of multiple myeloma: the evidence to date
Weisel, K. C. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s94531 · Cited by 15
Self-citationVogl, D. T., Delforge, M., Song, K., Guo, S., Gibson, C. J., Ervin-Haynes, A. L., & Facon, T. T. F. (2017) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2017.1334125 · Cited by 15
“idomide (MPT) [10], a regimen that was previously”
BackgroundMethodInfluentialSelf-citationMaintenance and continuous therapy for multiple myeloma
Richardson, P. G. G., Laubach, J. P., Gandolfi, S., Facon, T. T. F., Weisel, K. C., & O’Gorman, P. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1490181 · Cited by 13
“prednisone, and thalidomide (MPT) in TNE patients with NDMM [49].”
BackgroundSelf-citationTerpos, E., Katodritou, E., Symeonidis, A. S., Zagouri, F., Gerofotis, A., Christopoulou, G., Gavriatopoulou, M., Christoulas, D., Ntanasis‐Stathopoulos, I., Kourakli, A., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32125 · Cited by 14
Self-citationDjebbari, F., Panitsas, F. P., Eyre, T. A., Prodger, C. F., Davies, F., Burton, K., Khera, A., Vallance, G. D., Moore, S. E., Kothari, J., et al. (2020) · Haematologica · doi:10.3324/haematol.2019.240762 · Cited by 13
Network meta‐analysis of first‐line treatments in transplant‐ineligible multiple myeloma patients
Gil‐Sierra, M. D., Gimeno‐Ballester, V., Fenix-Caballero, S., & Rey, E. J. A. D. (2020) · European Journal Of Haematology · doi:10.1111/ejh.13407 · Cited by 13
Weisel, K. C., Dimopoulos, M. A., Moreau, P., Yağcı, M., Larocca, A., Kanate, A. S., Vural, F., Cascavilla, N., Basu, S., Johnson, P. R. E., et al. (2020) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2020.1747066 · Cited by 14
“continuous therapy with lenalidomide until disease progression is now standard practice based on improved survival outcomes demonstrated in randomized phase 3 clinical trials [20,21].”
MethodSelf-citationJimenez-Zepeda, V. H., Venner, C. P., McCurdy, A. B. R., Masih‐Khan, E., Atenafu, E. G., Sébag, M., Stakiw, J., Song, K., LeBlanc, R., Reiman, T., et al. (2021) · British Journal of Haematology · doi:10.1111/bjh.17350 · Cited by 14
“Bortezomib-containing regimens (BCRs) have been the standard frontline approach for transplant-ineligible multiple myeloma (TIMM) patients in Canada, based on the strength of the VISTA study.1,2 Most often, these included bortezomib, melphalan and prednisone (VMP) and cyclophosphamide, bortezomib and dexamethasone or…”
BackgroundMethodInfluentialSubsequent primary malignancies among multiple myeloma patients treated with or without lenalidomide
Rollison, D. E. M., Komrokji, R. S., Lee, J., Hampras, S. S., Fulp, W. J., Fisher, K. J., Baz, R., Nishihori, T., Xu, Q., Olesnyckyj, M., et al. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2016.1207763 · Cited by 12
Self-citationTreatment of Newly Diagnosed Elderly Multiple Myeloma
Fouquet, G., Gay, F., Boyle, E. M., Bringhen, S., Larocca, A., Facon, T. T. F., Leleu, X. P., & Palumbo, A. P. (2016) · Cancer treatment and research · doi:10.1007/978-3-319-40320-5_8 · Cited by 13
Self-citationPractical Considerations in Managing Relapsed Multiple Myeloma
Agarwal, A., Chow, E., Bhutani, M., Voorhees, P. M., Friend, R. N., & Usmani, S. Z. (2016) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2016.11.010 · Cited by 15
Practical Considerations for Antibodies in Myeloma
Laubach, J. P., van de Donk, N. W. C. J., Davies, F. E., & Mikhael, J. R. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_205443 · Cited by 14
Clinical treatment of newly diagnosed multiple myeloma
Cejalvo, M. J., & de la Rubia, J. (2015) · Expert Review of Hematology · doi:10.1586/17474086.2015.1078236 · Cited by 15
“Non-hematological toxicity was similar between treatment regimens [93].”
BackgroundMethodMcCormack, P. L. (2015) · Drugs & Aging · doi:10.1007/s40266-015-0269-6 · Cited by 13
“Patients in the two registration trials were newly diagnosed with symptomatic, measurable multiple myeloma and were ineligible for autologous stem-cell transplantation as a result of advanced age (aged C65 years) [19, 20], or because of refusal (due to cost or other reason) or comorbidities [19].”
BackgroundMethodInfluentialNathwani, N., Larsen, J. T., & Kapoor, P. (2016) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-016-0310-9 · Cited by 13
Determining treatment intensity in elderly patients with multiple myeloma
Salvini, M., D’Agostino, M., Bonello, F., Boccadoro, M., & Bringhen, S. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1496823 · Cited by 13
“[39].”
Antitumor effect of lenalidomide in malignant glioma cell lines
Hanashima, Y., Sano, E., Sumi, K., Ozawa, Y., Yagi, C., Tatsuoka, J., Yoshimura, S., Yamamuro, S., Ueda, T., Nakayama, T., et al. (2020) · Oncology Reports · doi:10.3892/or.2020.7543 · Cited by 14
“Clinically, the antitumor effect of lenalidomide was shown to be more effective than that of thalidomide in hematopoietic malignancies (8-12).”
BackgroundSanchez, L. J., Barley, K. M., Richter, J. R., Franz, J. K., Cho, H. J., Jagannath, S., Madduri, D., Parekh, S. S., Richard, S., & Chari, A. (2020) · Expert Review of Hematology · doi:10.1080/17474086.2020.1804356 · Cited by 12
Mian, H. S., Reece, D. E., Masih‐Khan, E., McCurdy, A. B. R., Kardjadj, M., Jimenez-Zepeda, V. H., Song, K., Louzada, M., LeBlanc, R., Sébag, M., et al. (2022) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2022.03.002 · Cited by 15
Self-citationKocaata, Z., Wilke, T., Fischer, F., Welte, R., & Einsele, H. (2022) · PharmacoEconomics - Open · doi:10.1007/s41669-022-00344-4 · Cited by 13
Cruz, M. P. (2016) · PubMed · Cited by 20
Merz, M., Kellermann, L., Poenisch, W., Tischler, H., Kohnke, J., Knauf, W. U., & Goldschmidt, H. (2017) · Annals of Hematology · doi:10.1007/s00277-017-2991-0 · Cited by 12
“After results from the FIRST trial comparing lenalidomide/ dexamethasone (Rd) with melphalan/thalidomide/dexamethasone (MPT) led to approval of Rd for newly diagnosed patients in early 2015 [15], we observed increasing application of lenalidomide as first-line treatment for transplant-ineligible patients.”
ResultIto, T., Konishi, A., Tsubokura, Y., Azuma, Y., Hotta, M., Yoshimura, H., Nakanishi, T., Fujita, S., Nakaya, A., Satake, A., et al. (2018) · Frontiers in Nutrition · doi:10.3389/fnut.2018.00072 · Cited by 12
“In a randomized phase 3 trial consisting of newly diagnosed MM patients, grade 3 or 4 fatigue was observed in 7 to 9 % of the patients administered LEN-DEX as a first line treatment (9).”
BackgroundExpert Panel Consensus Statement for Proper Evaluation of First Relapse in Multiple Myeloma
Offidani, M., Boccadoro, M., Raimondo, F. D., Petrucci, M. T., Tosi, P., & Cavo, M. (2019) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-019-00507-x · Cited by 14
Self-citationMoving Toward Continuous Therapy in Multiple Myeloma
Bonello, F., Cetani, G., Bertamini, L., Gay, F., & Larocca, A. (2019) · Clinical Hematology International · doi:10.2991/chi.d.191101.001 · Cited by 13
Drug resistance and minimal residual disease in multiple myeloma
Gozzetti, A., Ciofini, S., Sicuranza, A., Pacelli, P., Raspadori, D., Cencini, E., Tocci, D., & Bocchia, M. (2022) · Cancer Drug Resistance · doi:10.20517/cdr.2021.116 · Cited by 16
Next-Generation Sequencing Informing Therapeutic Decisions and Personalized Approaches
Szalat, R. E., & Munshi, N. C. (2016) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_159017 · Cited by 12
Mel, S. D., Chen, Y., Gopalakrishnan, S., Ooi, M. G. M., Teo, C., Tan, D., Teo, M., Tso, A. C. Y., Lee, L. Y. K., Nagarajan, C., et al. (2017) · Singapore Medical Journal · doi:10.11622/smedj.2016150 · Cited by 14
Where are we now with the treatment of multiple myeloma?
Morgan, G. J., & Rasche, L. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.82 · Cited by 12
Drug-induced olfactory and gustatory dysfunction: Analysis of FDA adverse events reporting system
Debbaneh, P. M., McKinnon, L., Haidari, M., & Liang, J. Z. (2023) · Auris Nasus Larynx · doi:10.1016/j.anl.2022.12.012 · Cited by 14
Nuances in the Management of Older People With Multiple Myeloma
Pawlyn, C., Gay, F., Larocca, A., Roy, V., & Ailawadhi, S. (2016) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-016-0323-4 · Cited by 11
Liu, X., Chen, J., He, Y., Meng, X., Li, K., He, C., & Liu, S. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s123680 · Cited by 11
Leleu, X. P., Kyriakou, C. A., Broek, I. V., Murphy, P. T., Bacon, P., Lewis, P., Gilet, H., Arnould, B., & Petrucci, M. T. (2017) · Blood Cancer Journal · doi:10.1038/bcj.2017.20 · Cited by 12
Cao, Y., Wan, N., Liang, Z., Xie, J., Wang, S., Lin, T.-F., Zhang, T., & Jiang, J. (2019) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2019.04.009 · Cited by 13
Djebbari, F., Sharpley, F. A., McLain-Smith, S., Vallance, G. D., Eyre, T. A., Kothari, J., Moore, S. E., & Ramasamy, K. (2020) · PLoS ONE · doi:10.1371/journal.pone.0229469 · Cited by 10
Mina, R., Belotti, A., Petrucci, M. T., Zambello, R., Capra, A., Lullo, G. D., Ronconi, S., Pescosta, N., Grasso, M., Monaco, F., et al. (2020) · Blood Cancer Journal · doi:10.1038/s41408-020-0326-1 · Cited by 12
Hannig, L. H., Nielsen, L. K., Ibsen, R., Arnheim‐Dahlström, L., Kjellberg, J., & Abildgaard, N. (2021) · European Journal Of Haematology · doi:10.1111/ejh.13615 · Cited by 11
Real life management of patients hospitalized with multiple myeloma in France
Dumontet, C., Couray‐Targe, S., Teisseire, M., Karlin, L., & Maucort‐Boulch, D. (2018) · PLoS ONE · doi:10.1371/journal.pone.0196596 · Cited by 12
Metadata
- Authors
- Benboubker, L., Dimopoulos, M. A., Dispenzieri, A., Catalano, J., Belch, A. R., Cavo, M., Pinto, A., Weisel, K., Ludwig, H., Bahlis, N., Banos, A., Tiab, M., Delforge, M., Cavenagh, J., Geraldes, C., Lee, J.-J., Chen, C., Oriol, A., de la Rubia, J., Qiu, L., White, D. J., Binder, D., Anderson, K., Fermand, J.-P., Moreau, P., Attal, M., Knight, R., Chen, G., Van Oostendorp, J., Jacques, C., Ervin-Haynes, A., Avet-Loiseau, H., Hulin, C., & Facon, T.
- Affiliations
- National and Kapodistrian University of Athens (GR)
- Mayo Clinic (US)
- Frankston Hospital (AU)
- University of Alberta (CA)
- Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT)
- University of Tübingen (DE)
- Wilhelminen Hospital (AT)
- University of Calgary (CA)
- Centre Hospitalier de la Côte Basque (FR)
- Universitair Ziekenhuis Leuven (BE)
- St Bartholomew's Hospital (GB)
- Unidade Local de Saúde de Coimbra (PT)
- Chonnam National University Hwasun Hospital (KR)
- Princess Margaret Cancer Centre (CA)
- Josep Carreras Leukaemia Research Institute (ES)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Dalhousie University (CA)
- Kantonsspital Winterthur (CH)
- Dana-Farber Cancer Institute (US)
- Hôpital Saint-Louis (FR)
- Hôpital Purpan (FR)
- Celgene (United States) (US)
- Centre Hospitalier Régional et Universitaire de Nancy (FR)
- Centre Hospitalier Universitaire de Lille (FR)
- ORCID
- Benboubker, Lotfi
- Dimopoulos, Meletios A.
- Dispenzieri, Angela
- Belch, Andrew R.
- Weisel, Katja
- Ludwig, Heinz
- Bahlis, Nizar
- Banos, Anne
- Geraldes, Catarina
- Lee, Je-Jung
- Chen, Christine
- Oriol, Albert
- Qiu, Lugui
- White, Darrell J.
- Anderson, Kenneth
- Fermand, Jean-Paul
- Moreau, Philippe
- Attal, Michel
- Knight, Robert
- Chen, Guang
- Jacques, Christian
- Hulin, Cyrille
- Facon, Thierry
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-09-04
- Volume
- 371
- Issue
- 10
- Pages
- 906-917
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2141105112
- Cited by
- 793
- References
- 38
- Citations by year
- 2026: 18 · 2025: 41 · 2024: 39 · 2023: 37 · 2022: 54 · 2021: 74 · 2020: 89 · 2019: 75 · 2018: 80 · 2017: 92 · 2016: 102 · 2015: 76 · 2014: 15
- FWCI
- 67.35
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Keywords
- lenalidomide, dexamethasone, multiple myeloma, transplant-ineligible patients, progression-free survival, overall survival, treatment duration, adverse events, second primary malignancy, infection, neurotoxicity, hematologic toxicity, newly diagnosed multiple myeloma
- MeSH terms
- Lenalidomide, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Dexamethasone, Female, Humans, Male, Melphalan, Middle Aged, Multiple Myeloma, Prednisone, Thalidomide, Disease-Free Survival, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.